Literature DB >> 25583622

Antithrombotic therapy in 2014: Making headway in anticoagulant and antiplatelet therapy.

Jawed Fareed1.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25583622     DOI： 10.1038/nrcardio.2014.222

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  How I treat target-specific oral anticoagulant-associated bleeding.

Authors:  Deborah M Siegal; David A Garcia; Mark A Crowther
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

3.  Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.

Authors:  Nevin C Baker; Michael J Lipinski; Thibault Lhermusier; Ron Waksman
Journal:  Circulation       Date:  2014-10-07       Impact factor: 29.690

4.  'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.

Authors:  Gregory Y H Lip; Cécile Laroche; Gheorghe-Andrei Dan; Massimo Santini; Zbigniew Kalarus; Lars Hvilsted Rasmussen; Popescu Mircea Ioachim; Otilia Tica; Giuseppe Boriani; Paolo Cimaglia; Igor Diemberger; Camilla Fragtrup Hellum; Bettina Mortensen; Aldo P Maggioni
Journal:  Am J Med       Date:  2014-01-28       Impact factor: 4.965

5.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

6.  Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors:  Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal:  Circulation       Date:  2011-09-06       Impact factor: 29.690

7.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Authors:  Genmin Lu; Francis R DeGuzman; Stanley J Hollenbach; Mark J Karbarz; Keith Abe; Gail Lee; Peng Luan; Athiwat Hutchaleelaha; Mayuko Inagaki; Pamela B Conley; David R Phillips; Uma Sinha
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

Review 8.  Treatment of venous thromboembolism.

Authors:  Philip S Wells; Melissa A Forgie; Marc A Rodger
Journal:  JAMA       Date:  2014-02-19       Impact factor: 56.272

9.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

10.  Use of PER977 to reverse the anticoagulant effect of edoxaban.

Authors:  Jack E Ansell; Sasha H Bakhru; Bryan E Laulicht; Solomon S Steiner; Michael Grosso; Karen Brown; Victor Dishy; Robert J Noveck; James C Costin
Journal:  N Engl J Med       Date:  2014-11-05       Impact factor: 91.245
  10 in total
  3 in total

Review 1.  "Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation.

Authors:  Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Semin Thromb Hemost       Date:  2015-09-26       Impact factor: 4.180

2.  Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu.

Authors:  Xuejie Chen; Da-Yun Jin; Darrel W Stafford; Jian-Ke Tie
Journal:  Blood       Date:  2018-08-08       Impact factor: 22.113

Review 3.  Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Authors:  Andreas Zirlik; Christoph Bode
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.